000			02922nam a22003495i 4500
001			320582
003			MX-SnUAN
005			20160429161426.0
007			cr nn 008mamaa
008			160111s2015 gw | s |||| 0|eng d
020			_a9783319186184 _9978-3-319-18618-4
035			_avtls000421070
039		9	_y201601110954 _zstaff
050		4	_aRB155.8
245	1	0	_aRegulatory aspects of gene therapy and cell therapy products : _ba global perspective / _cedited by Maria Cristina Galli, Mercedes Serabian.
264		1	_aCham : _bSpringer International Publishing : _bSpringer, _c2015.
300			_axii, 230 páginas : _b23 ilustraciones, 17 ilustraciones en color.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aAdvances in Experimental Medicine and Biology, _x0065-2598 ; _v871
500			_aSpringer eBooks
505	0		_a1. Regulatory Oversight of Gene Therapy and Cell Therapy Products in the US - FDA/CBER -- 2. US Oversight of Gene Therapy Products – NIH RAC -- 3. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Canada - Health Canada -- 4. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products -- 5. Regulation of Clinical Trials with Advanced Therapy Medicinal Products (ATMP) in Germany -- 6. EU Clinical Trials Regulatory Oversight of Advanced Therapy Medicinal Products (ATMP): Perspectives from Various Member States -- 7. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Switzerland - Swissmedic -- 8. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Japan - Japan Ministry of Health, Labour and Welfare (MHLW) and Pharmaceutical and Medical Device Agency (PMDA) -- 9. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea - Korean Ministry of Food and Drug Safety (MFDS) -- 10. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Taiwan - Taiwan Food and Drug Administration (TFDA) -- 11. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Singapore - Singapore Health Science Authorities (HSA) -- 12. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Brazil - National Health Surveillance Agency (ANVISA).
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aGalli, Maria Cristina, _eeditor. _9365321
700	1		_aSerabian, Mercedes, _eeditor. _9365322
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9783319186177
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-319-18618-4 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c320582 _d320582